Childhood obesity is on the rise and is becoming an epidemic in our country and worldwide. The consequences of childhood ...

A MAP has revealed England's fattest towns with the highest obesity rates. The latest statistics from the NHS have documented the percentage of people who are classed as obese and overweight by ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

New data from the U.S. Centers for Disease Control and Prevention (CDC) shows that over half of U.S. states have either "high" or "very high" levels of SARS-CoV-2—the virus that causes COVID-19 ...

Prostock-Studio/Getty So far this year, 33,387 cases have been reported to the U.S. Centers for Disease Control and Prevention (CDC). Whooping cough, also known as pertussis, is a highly ...

WalletHub's ranking of the cities with the highest levels of "excesses and vices" may land those areas on Santa's Naughty ...

In the CDC, we’ll observe how CDC director nominee ... administration to extend Medicare coverage for semaglutide anti-obesity drugs. Read more of what we’re watching. MAHA CAUCUS — Members ...

In a first, scientists at the World Health Organisation (WHO) have endorsed a new class of medicines known as GLP-1 receptor agonists, which mimic a hormone that regulates appetite and blood sugar ...

In a study, people who took Zepbound had fewer breathing interruptions. The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...

LONDON/COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

The numbers showed that both average body mass index (BMI) and obesity rates across the population fell in 2023, having risen steadily since 2013 before leveling in 2022. While we don't yet have any ...

A new type of obesity drug being developed by Novo Nordisk has fallen short of expectations set by the company in a closely watched Phase 3 trial, causing shares to lose nearly a fifth of their value ...